dihexa safety human studies Growth factors and their peptide mimetics for treatment of traumatic brain injury dihexa human trial Dihexa in

Two Alternative Routes From Peptides to Non-peptidic Molecules The entire spectrum of molecules is schematically represented in the following diagram

The large phase 3 EVOKE trials in people who already had mild cognitive impairment or mild Alzheimers did not slow the disease, but the observational signal for prevention is strong, with real-world data from more than a million patients showing that semaglutide users have a 40 to 70 percent lower risk of a first Alzheimers diagnosis than users of other diabetes drugs

GHK-Cu helps stimulate collagen and elastin production, which are the building blocks of firm, smooth skin

The program receives ~150 applications annually, yielding ~3-5% acceptance rate